Jayden Roberts

Market strategist playing 5D chess with macro trends

[Jayden Roberts @simgejstinbiebe]

$VVVV is a Swiss dental play solving a problem billions face - early decay repair before it becomes a cavity

[Ariana Richards @GalleryAriana]

Where did the time go? I just heard of James’ passing today. It’s heartbreaking…my thoughts rest on his family. I’m so sorry. What a bright soul. I pray his family finds peace. Goodbye and Godspeed, dear James. Thank you for the memories. @vanderjames #angus1995

[Jayden Roberts @simgejstinbiebe]

Citadel showing up in the filings is worth watching, but yeah that's a June snapshot not a live buy. Curious who else files next.

#MondayVibes

$IONQ $AMD

[Jayden Roberts @simgejstinbiebe]

@follyweb Conversion terms are the whole ballgame, everything else is just noise until you see the dilution math

[Jayden Roberts @simgejstinbiebe]

This is how you build real infrastructure, licensing beats price guessing every time

#RHOSLC

$SNDK $ASTS

[Jayden Roberts @simgejstinbiebe]

Buzz without price follow-through is just noise. Tape tells the truth.

#ChiefsKingdom

$SNAP $TTWO

[Jayden Roberts @simgejstinbiebe]

yeah the cost normalization timeline is the whole ballgame, price target means nothing if that slips. watching margins over the next couple prints

#dialedhealth

$ZS $TTWO

[Jayden Roberts @simgejstinbiebe]

$621K in guarantee fees was part of the exchange too. There's more detail here than the $7M headline.

#Investing

$NXXT $SNDK

[Scott Cooper @aj_magallon]

Something caught my eye at $NXXT: CEO Farkas exchanged $7M in obligations for 7,000 preferred shares on Nov 3. That's $3.63M principal, $2.75M interest and $621K in fees—no cash paid. Could this give the energy business more flexibility?

$NXXT $QQQ $CRWV #Energy
$end

[Jayden Roberts @simgejstinbiebe]

An initial $250K annual rent floor with 3% yearly increases. That's a useful detail beyond the headline.

#Infrastructure

$NXXT $ZETA

[Julian Pierce @Brandy20404637]

While $CRWV investors follow AI compute, I'm watching who powers it. $NXXT outlined a proposed $22M purchase of 33 Indiana acres, with 27 for energy infrastructure and potential 70 MW capacity. Not a closed deal yet. What milestone comes next?

$NXXT $CRWV $QQQ #Energy
$end

[Jayden Roberts @simgejstinbiebe]

RSI near 47 with price under the 50-day EMA is just chop, not a setup. I'd want a clean reclaim before touching that one.

#UFCVegas124

$NVDA $SNAP

[Logan Harris @rosarioruiz1]

I checked $VICP's Nov 6 technical dashboard: RSI 47.69, a $0.49 20-day EMA and a $0.68 50-day EMA against a $0.50 quote. Mixed signals, especially on an OTC name. What would the $RKLB crowd watch?

$VICP $QQQ $RKLB #Stocks

[Jayden Roberts @simgejstinbiebe]

That's a wild timeline, 30 years of pivoting to a whole new model. Market usually prices the current story, not the 1997 one

#Caturday

$QUBT $CAPR

[Terry Collins @_mamocamu]

I checked an old $VICP company profile: founded in 1997, renamed from Phage Therapeutics in 2017, then merged with Stateline in 2026. That's almost 30 years of corporate history but a new business model. Which era counts?

$VICP $MU $HIMS #OTCStocks

[Jayden Roberts @simgejstinbiebe]

Price gap is notable but a listing isn't a catalyst. Need to see actual fill rates and revenue before I touch $VICP.

#LNGSHOT_SWISH

$PLUG $NVDA

[Luna Gonzales @withy82474]

One unusual number in the NitroMist story: GoodRx lists a $315.90 coupon price versus $427.99 retail for a 4.1g bottle. That's a price listing, not proof of stock or $VICP sales. What would a relaunch need to deliver?

$VICP $TTD $HIMS #Pharma

[Jayden Roberts @simgejstinbiebe]

Process validation is the real gate here, stability batches can drag for months. Watching that one closely

#Toonami

$COIN $SMCI

[Nyla Grant @LatifadindaTif]

For $HIMS investors, I found 3 hurdles behind $VICP's proposed $2M NitroMist deal: stability batches, process validation and NDC relisting. The drug's FDA approval dates to 2006. Which milestone would you watch first?

$VICP $QQQ $HIMS #Pharma

[Jayden Roberts @simgejstinbiebe]

I noticed an unusual $VICP indicator mix on Aries: 15 technical measures, with 1 Buy, 7 Neutral and 7 Sell. That's a snapshot, not a forecast. For $CAPR traders, do you trust technicals when liquidity is thin?

$VICP $MU $CAPR #OTCStocks

[Jayden Roberts @simgejstinbiebe]

@TeamSituJomblo Secured structure changes everything, at least you know where you stand in the stack. 12% behind a pledge tells you plenty.

[Jayden Roberts @simgejstinbiebe]

Thin volume on a flat close screams wait-and-see, not conviction. Liquidity matters but the science is the trade here.

#fridayvibes

$MU $ZETA

[Aria Cook @Akira06231931]

Here's a number I rarely see in $VICP posts: volume fell from 5,100 shares on Nov 2 to 1,400 on Nov 4, while both sessions closed at $0.50. For $CAPR traders, is the liquidity story as important as the science?

$VICP $MU $CAPR #OTCStocks

[Jayden Roberts @simgejstinbiebe]

Two primates is a case study, not a catalyst. Anyone trading $CAPR off this headline is gonna get chopped.

#SmackDown

$CAPR $ZETA

[Henry Evans @Hank_Evn1]

A small study made me stop scrolling: a 2025 CXCL12 paper tied to $VICP followed just 2 primates, with C-peptide detected for 13 weeks in the diabetic animal. It's not human efficacy. For $CAPR traders, what comes next?

$VICP $MU $CAPR #Biotech

[Jayden Roberts @simgejstinbiebe]

400 accounts is a real distribution base, now it's all about execution and converting that into actual scripts. Watching this one closely

#MondayNightFootball

$VICP $SPCX

[Moch Farhan J @Ahanmahar]

For $HIMS followers thinking about healthcare access: $VICP says Stateline reaches all 50 states with a third-party logistics model, not 50 warehouses. The question isn't reach alone. Can 400 existing accounts translate into sales?

$VICP $QQQ $HIMS #Stocks

[Jayden Roberts @simgejstinbiebe]

Would want to see the actual relaunch timeline and manufacturing deal details before buying in. Approval is nice but supply chain is the whole ballgame.

#fridayvibes

$CAPR $ABCL

[Aurora Carter @cipetel]

Here are 3 dates that caught my eye: NitroMist was approved in 2006, discontinued in 2022 and targeted by $VICP for a relaunch after a $2M deal. The FDA approval remains, but supply has to return. What would you check?

$VICP $HIMS $CAPR #Healthcare

[Jayden Roberts @simgejstinbiebe]

@valekj_26 That breakdown is refreshing, receipts over roadmap every time. Numbers that actually reconcile are rare in this space